Immunoregulating properties of peptides related to tumor rejection antigens: Effect on human monocytes and natural killer cells

Journal of Immunotherapy

Volumn 23, Issue 2, 2000, Pages 215-224

  Pérez Díez, Ainhoa ^a   Martínez Crespo, Alejandro ^a   Pérez Mediavilla, L Alberto ^a   Santiago, Esteban ^a   López Moratalla, Natalia ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Cytokine; DNase; MAGE; Nitric oxide synthase; NK activity; Tyrosinase

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; DEOXYRIBONUCLEASE; GAMMA INTERFERON; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 6; MONOPHENOL MONOOXYGENASE; NITRIC OXIDE SYNTHASE; SYNTHETIC PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR REJECTION ANTIGEN;

ARTICLE; CELL MEDIATED CYTOTOXICITY; CELL STRAIN K 562; CONTROLLED STUDY; CYTOKINE RELEASE; DAUDI CELL; HUMAN; HUMAN CELL; IMMUNOREGULATION; IMMUNOSTIMULATION; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA CELL; MONOCYTE; MONONUCLEAR CELL; NATURAL KILLER CELL; PEPTIDE SYNTHESIS; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; CYTOKINES; CYTOPLASMIC GRANULES; DEOXYRIBONUCLEASES; ENZYME INDUCTION; HUMANS; IMMUNOPHENOTYPING; K562 CELLS; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; MONOCYTES; NITRIC OXIDE SYNTHASE; PEPTIDES; TUMOR CELLS, CULTURED;

EID: 0343238853     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200003000-00006     Document Type: Article

References (47)

1. Boon T, Cerottini JC, Van Den Eynde B, Van Der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-65.
2. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regresion antigens. Immunol Today 1997; 18:175-82.
3. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor-alpha. J Exp Med 1994; 179:1109-18.
4. Jonuleit H, Knop J, Enk AH. Cytokines and their effects on maturation, differentiation and migration of dendritic cells. Arch Dermatol Res 1996;289:1-8.
5. Labeur MS, Roters B, Pers B, et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 1999;162:168-75.
6. Czerniecki BJ, Carter C, Rivoltini L, et al. Calcium ionophoretreated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells. J Immunol 1997; 159:3823-37.
7. + blood monocytes exhibits features of tissue macrophages. Eur J Immunol 1993;23:2053-8.
8. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996;272:50-4.
9. Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 1995;13: 437-57.
10. Jonuleit H, Kuhn U, Müller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997;27:3135.
11. Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood: an improved method with special regard to clinical applicability. J Immunol Methods 1996;196:137-51.
12. Reddy A, Sapp M, Feldman M, Subklewe M, Bhardwaj N. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritc cells. Blood 1997;90:3640-6.
13. López-Moratalla N, López-Zabalza MJ, Subirá ML, et al. Immunomodulation induced by synthetic peptides derived from Staphylococcus aureus protein A. Biochim Biophys Acta 1994;1221: 153-8.
14. López-Moratalla N, Calonge MM, López-Zabalza MJ, et al. Activation of human lymphomononuclear cells by peptides derived from extracellular matrix proteins. Biochim Biophys Acta 1995; 1265:181-8.
15. López-Moratalla N, Ruíz E, López-Zabalza MJ, Santiago E. A common structural motif in immunopotentiating peptides with sequences present in human autoantigens. Elicitation of a response mediated by monocytes and ThI cells. Biochim Biophys Acta 1996;1317:183-91.
16. - induced by short immunomodulating peptides. Biochem Biophys Res Commun 1994;205:2008-12.
17. Boyum A. Isolation of human blood monocytes with Nycodenz, a new non-ionic iodinated gradient medium. Scand J Immunol 1983; 17:429-36.
18. Merrifield RB. Solid phase peptide synthesis I. The synthesis of a tetrapeptide. J Am Chem Soc 1963;85:2149.
19. Zakut R, Topalian SL, Kawakami Y, et al. Differential expression of MAGE-1,-2 and -3 messenger RNA in transformed and normal human cell lines. Cancer Res 1993;53:5-8.
20. Pérez-Mediavilla LA, López-Zabalza MJ, Calonge M, et al. Inducible nitric oxide synthase in human lymphomononuclear cells activated by synthetic peptides derived from extracellular matrix proteins. FEBS Lett 1995;357:121-4.
21. Podack ER, Young JD, Cohn ZA. Isolation and biochemical and functional characterizacion of perform 1 from cytolytic T cell granules. Proc Natl Acad Sci USA 1985;82:8629-33.
22. Gross-Bellard M, Oudet P, Chambon P. Isolation of high-molecular-weight DNA from mammalian cells. Eur J Biochem 1973;36:32-8.
23. Kwon BS, Hat AK, Pomerantz SH, Halaban R. Isolation and sequence of a cDNA clone for human tyrosinase that maps at the mouse c-albino locus. Proc Natl Acad Sci USA 1987;84: 7473-7.
24. Imai Y, Shichijo S, Yamada A, et al. Sequence analysis of the MAGE gene family encoding human tumor-rejection antigens. Gene 1995;160:287-90.
25. Feinman R, Henriksen-De Stefano A, Tsujimoto M, Vilcek J. Tumor necrosis factor is an important mediator of tumor cell killing by human monocytes. J Immunol 1987;138:635-40.
26. Ziegler-Heitbrock HW, Moller LA, Linke RP, et al. Tumor necrosis factor as effector molecule in monocyte mediated cytotoxicity. Cancer Res 1986;46:5947-52.
27. Greene AL, Makrigiannis AP, Fitzpatrick L, Hoskin DW. Anti-CD3-Activated killer T cells: interleukin-6 modulates the induction of major histocompatibility complex-unrestricted cytotoxicity and the expression of genes coding for cytotoxic effector molecules. J Interferon Cytokine Res 1997;17:727-37.
28. López-Zabalza MJ, Martínez-Lausin S, Bengoechea-Alonso MT, et al. Signaling pathway triggered by a short immunomodulating peptide on human monocytes. Arch Biochem Biophys 1997;338: 136-42.
29. + T cell subsets and induces early resistant to Leishmania major in mice. J Exp Med 1993;178: 567-77.
30. Orange JS, Wang B, Terhorst C, Biron CA. Requirement of natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 adminstration. J Exp Med 1995;182:1045-56.
31. Higashi N, Nishimura Y, Higuchi M, Osawa T. Human monocytes in a long-term culture with interleukin-2 show high tumoricidal activity against various tumor cells. Immunotherapy 1991;10:247-55.
32. López-Moratalla N, Calleja A, González A, et al. Inducible nitric oxide synthase in monocytes from patients with Graves disease. Biochem Biophys Res Commun 1996;226:723-9.
33. Martin JH, Edwards SW. Interferon-gamma enhances monocyte cytotoxicity via enhanced reactive oxygen intermediate production. Absence of an effect on macrophage cytotoxicity is due to failure to enhance reactive nitrogen intermediate production. Immunology 1994;81:592-7.
34. Hibbs JB, Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1988;157:87-94.
35. Keller R, Keist R. Abilities of activated macrophages to manifest tumoricidal activity and to generate reactive nitrogen intermediates: a comparative study in vitro and in vivo. Biochem Biophys Res Commun 1989;164:968-73.
36. Cui S, Reichner JS, Mateo RB, Albina JE. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms. Cancer Res 1994;54: 2462-7.
37. Pio R, López-Zabalza MJ, Rouzaut A, Santiago E, López-Moratalla N. Nitric oxide activates granule-associated DNase in human monocytes. Nitric Oxide 1998;2:165-73.
38. Zembala M, Siedlar M, Marcinkiewicz J, Pryjma J. Human monocytes are stimulated for nitric oxide release in vitro by some tumor cells but not by cytokines and lipopolysaccharide. Eur J Immunol 1994;24:435-9.
39. Andreesen R, Scheibenbogen C, Brugger W, et al. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res 1990;50:7450-6.
40. Faradji A, Bohbot A, Schmitt-Goguel M, et al. Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small cell lung cancer: toxicity and immunomodulatory effects. Cancer Immunol Immunother 1991;33:319-26.
41. Garrido F, Ruíz-Cabello F, Cabrera TJ, et al. Immplications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today 1997;18:89.
42. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487-94.
43. Rosenberg SA. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. In: De Vita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia: JB Lippincott, 1986, pp 55-91.
44. + lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide. Crit Rev Immunol 1998;18:87-98.
45. + T cells in the antitumor immune response. J Exp Med 1998; 188:2357-2368.
46. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998;188:2199-2204.
47. h2 responses: a key role for the natural immune response? Immunol Today 1992;13:379-81.